Laverock Therapeutics to demonstrate at the European Society of Gene & Cell Therapy
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.
Artificial Intelligence (AI), has emerged as a disruptive force with the potential to revolutionise industries across the globe. For investors and shareholders, AI represents a compelling opportunity.
Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.
Scancell achieve significant milestone for their cancer vaccine.
Calculus Q2 2023 Quarterly Update showcasing some great news stories from our portfolio companies.
Its new documentary explores the legacy of famed music art studio Hipgnosis.
The new trial is designed to build on preliminary data supporting the notion that OBT-076 is able to deliver immune priming in chemo-refractory, advanced cancer patients.
The collaboration will see a new Phase 1b trial undertaken, investigating OBT’s lead asset, OBT076, in patients with Adenoid Cystic Carcinoma (ACC), a rare and aggressive type of cancer
The grant from the Medical Technology Enterprise Consortium (MTEC) will support the continued development of its fully portable handheld DeepView device
CEO, John Glencross quoted in this article regarding the potential removal of the sunset clause.